Axa S.A. Cytom X Therapeutics, Inc. Transaction History

Axa S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.53 - $2.89 $370,413 - $699,669	-242,100 Closed	0 $0
Q1 2022 Feb 14, 2023	BUY	$2.67 - $4.68 $646,407 - $1.13 Million	242,100 New	242,100 $646,000
Q1 2022 May 13, 2022	SELL	$2.67 - $4.68 $23,496 - $41,184	-8,800 Reduced 3.51%	242,100 $646,000
Q4 2021 Feb 14, 2022	BUY	$3.87 - $7.39 $74,691 - $142,627	19,300 Added 8.33%	250,900 $1.09 Million
Q3 2021 Nov 15, 2021	BUY	$4.32 - $6.43 $1 Million - $1.49 Million	231,600 New	231,600 $1.18 Million
Q1 2021 May 14, 2021	SELL	$6.6 - $9.0 $1.58 Million - $2.16 Million	-239,650 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$6.47 - $7.9 $508,050 - $620,339	78,524 Added 48.73%	239,650 $1.57 Million
Q3 2020 Nov 13, 2020	BUY	$6.55 - $8.83 $475,530 - $641,058	72,600 Added 82.01%	161,126 $1.07 Million
Q2 2020 Aug 14, 2020	BUY	$7.4 - $14.64 $655,092 - $1.3 Million	88,526 New	88,526 $737,000

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.